Maria Kuzikov

The paper identifies host-targeting antivirals against SARS-CoV-2 using morphological profiling, finding compounds that reverse infected cell phenotypes and validate host processes hijacked by viruses.

The paper optimizes and evaluates two cell-based assays for degrader discovery, finding that the signal rescue assay reliably identifies active degraders and filters out non-specific compounds.

The paper develops a machine learning model to predict drug-induced phospholipidosis using a large dataset of repurposed drugs tested across multiple cell lines.

The paper identifies CPI-169 as a competitive inhibitor of SARS-CoV-2 PLpro that targets the same binding site as GRL-0617, through a drug repurposing screening approach that accounts for redox-sensitivity.

The paper identifies 62 new inhibitors of SARS-CoV-2 3CL-Pro through a compound repurposing screen and validates their activity using X-ray crystallography.